RxDoctor Payments Data

Anne Tuskey, MD

Gastroenterology · Charlottesville, VANPI 1881754075

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 1 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Janssen Scientific Affairs, LLC. That places this record below the midpoint for gastroenterology clinicians in VA, where the typical reported total is $3,407.

$25in general payments, 2019–2025

Across 1 payment — averaging $24.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Scientific Affairs, LLC$25
$993,596in research payments, 2019–2025

Across 179 payments — averaging $5550.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$529K
  • Gilead$231K
  • Eli Lilly$159K
  • AbbVie$31K
  • Boehringer Ingelheim International GmbH$22K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$13K
  • plus $8K from 1 others

What the payments were for

  • Food & beverage$25100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Janssen Scientific Affairs, LLC1$25

How this compares

$25 in reported general payments places this provider in the 5th percentile of 473 gastroenterology providers in Virginia.

See all gastroenterology providers in Virginia

Medicare billing

Part B allowed, 2024
$42,888
Medicare patients
188
Services billed
351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab111$3,062,036
Skyrizi On-BodyRisankizumab-Rzaa25$511,373
EntyvioVedolizumab27$232,958
HumiraAdalimumab14$182,203
Mesalamine28$16,208
Sulfasalazine21$989
LoperamideLoperamide Hcl21$515
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl28$419
Dicyclomine Hcl15$246
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl13$216
Sodium Chloride0.9 % Sodium Chloride35$142
MethotrexateMethotrexate Sodium17$54

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →